Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

1. Hurvitz, S.A.
2. Bardia, A.
3. Quiroga, V.
4. Park, Y.H.
5. Blancas, I.
6. Alonso-Romero, J.L.
7. Vasiliev, A.
8. Adamchuk, H.
9. Salgado, M.
10. Yardley, D.A.
11. Berzoy, O.
12. Zamora-Auñón, P.
13. Chan, D.
14. Spera, G.
15. Xue, C.
16. Ferreira, E.
17. Badovinac Crnjevic, T.
18. Pérez-Moreno, P.D.
19. López-Valverde, V.
20. Steinseifer, J.
21. Fernando, T.M.
22. Moore, H.M.
23. Fasching, P.A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/S1470-2045(23)00268-1 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus